J&J jumps as pharma sales save growth

16 April 2019

Shares in US healthcare giant Johnson & Johnson (NYSE: JNJ) were up by nearly 3% after half-an-hour's trading on Tuesday following the company’s quarterly results presentation.

A 4.1% rise in sales in the company’s Pharmaceutical segment, which came in at $10.2 billion, offset decreases in both the Consumer and Medical Devices sector to ensure overall revenue crept up to $20 billion, up 0.1% compared to the first quarter of 2018.

"We remain focused on investing in innovative technologies and platforms"While diluted earnings per share (EPS) were down by 13.1% at $1.39, a decline attributed to the lawsuits that J&J is facing over its baby talcum powder, the adjusted EPS figure of $2.10 was a 1.9% increase.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK